445 related articles for article (PubMed ID: 20180615)
1. Unfractionated heparin dosing for venous thromboembolism in morbidly obese patients: case report and review of the literature.
Myzienski AE; Lutz MF; Smythe MA
Pharmacotherapy; 2010 Mar; 30(3):324. PubMed ID: 20180615
[TBL] [Abstract][Full Text] [Related]
2. Use of a modified dosing weight for heparin therapy in a morbidly obese patient.
Schwiesow SJ; Wessell AM; Steyer TE
Ann Pharmacother; 2005 Apr; 39(4):753-6. PubMed ID: 15741422
[TBL] [Abstract][Full Text] [Related]
3. Higher Maximum Doses and Infusion Rates Compared with Standard Unfractionated Heparin Therapy Are Associated with Adequate Anticoagulation without Increased Bleeding in Both Obese and Nonobese Patients with Cardiovascular Indications.
Floroff CK; Palm NM; Steinberg DH; Powers ER; Wiggins BS
Pharmacotherapy; 2017 Apr; 37(4):393-400. PubMed ID: 28107569
[TBL] [Abstract][Full Text] [Related]
4. Identifying optimal initial infusion rates for unfractionated heparin in morbidly obese patients.
Riney JN; Hollands JM; Smith JR; Deal EN
Ann Pharmacother; 2010; 44(7-8):1141-51. PubMed ID: 20587743
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of an Unfractionated Heparin Pharmacy Dosing Protocol for the Treatment of Venous Thromboembolism in Nonobese, Obese, and Severely Obese Patients.
Hosch LM; Breedlove EY; Scono LE; Knoderer CA
Ann Pharmacother; 2017 Sep; 51(9):768-773. PubMed ID: 28511582
[TBL] [Abstract][Full Text] [Related]
6. Unfractionated heparin infusion for treatment of venous thromboembolism based on actual body weight without dose capping.
Shlensky JA; Thurber KM; O'Meara JG; Ou NN; Osborn JL; Dierkhising RA; Mara KC; Bierle DM; Daniels PR
Vasc Med; 2020 Feb; 25(1):47-54. PubMed ID: 31623539
[TBL] [Abstract][Full Text] [Related]
7. Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients.
Ludwig KP; Simons HJ; Mone M; Barton RG; Kimball EJ
Ann Pharmacother; 2011 Nov; 45(11):1356-62. PubMed ID: 22009998
[TBL] [Abstract][Full Text] [Related]
8. Limitations of a standardized weight-based nomogram for heparin dosing in patients with morbid obesity.
Barletta JF; DeYoung JL; McAllen K; Baker R; Pendleton K
Surg Obes Relat Dis; 2008; 4(6):748-53. PubMed ID: 18586569
[TBL] [Abstract][Full Text] [Related]
9. Computer-assisted dosing of heparin. Management with a pharmacy-based anticoagulation service.
Kershaw B; White RH; Mungall D; Van Houten J; Brettfeld S
Arch Intern Med; 1994 May; 154(9):1005-11. PubMed ID: 8179443
[TBL] [Abstract][Full Text] [Related]
10. Use of subcutaneous lepirudin in an obese surgical intensive care unit patient with heparin resistance.
Inman KR; Gerlach AT
Ann Pharmacother; 2009 Oct; 43(10):1714-8. PubMed ID: 19690218
[TBL] [Abstract][Full Text] [Related]
11. Unfractionated heparin dosing for therapeutic anticoagulation in critically ill obese adults.
Hohner EM; Kruer RM; Gilmore VT; Streiff M; Gibbs H
J Crit Care; 2015 Apr; 30(2):395-9. PubMed ID: 25534987
[TBL] [Abstract][Full Text] [Related]
12. Delayed efficient anticoagulation with heparin in patients with a weight of 110 kg and more treated for acute coronary syndrome.
Joncas SX; Poirier P; Ardilouze JL; Carrier N; Fayad T; Farand P
Obesity (Silver Spring); 2013 Sep; 21(9):1753-8. PubMed ID: 23404940
[TBL] [Abstract][Full Text] [Related]
13. Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes.
Melloni C; Alexander KP; Chen AY; Newby LK; Roe MT; Allen LaPointe NM; Pollack CV; Gibler WB; Ohman EM; Peterson ED;
Am Heart J; 2008 Aug; 156(2):209-15. PubMed ID: 18657648
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous unfractionated heparin for the treatment of venous thromboembolism.
Kearon C
Curr Opin Pulm Med; 2007 Sep; 13(5):398-402. PubMed ID: 17940484
[TBL] [Abstract][Full Text] [Related]
15. Achievement of anticoagulation by using a weight-based heparin dosing protocol for obese and nonobese patients.
Spruill WJ; Wade WE; Huckaby WG; Leslie RB
Am J Health Syst Pharm; 2001 Nov; 58(22):2143-6. PubMed ID: 11760916
[TBL] [Abstract][Full Text] [Related]
16. Heparin and low-molecular-weight heparin therapy for venous thromboembolism. The twilight of anticoagulant monitoring.
Hull RD; Pineo GF; Stein P
Int Angiol; 1998 Dec; 17(4):213-24. PubMed ID: 10204652
[TBL] [Abstract][Full Text] [Related]
17. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis.
Hull RD; Raskob GE; Brant RF; Pineo GF; Valentine KA
Arch Intern Med; 1997 Dec 8-22; 157(22):2562-8. PubMed ID: 9531224
[TBL] [Abstract][Full Text] [Related]
18. Use of low-molecular-weight heparin to bridge therapy in obese patients and in patients with renal dysfunction.
George-Phillips KL; Bungard TJ
Pharmacotherapy; 2006 Oct; 26(10):1479-90. PubMed ID: 16999658
[TBL] [Abstract][Full Text] [Related]
19. Appropriate use of heparin. Empiric vs nomogram-based dosing.
Gunnarsson PS; Sawyer WT; Montague D; Williams ML; Dupuis RE; Caiola SM
Arch Intern Med; 1995 Mar; 155(5):526-32. PubMed ID: 7864708
[TBL] [Abstract][Full Text] [Related]
20. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
